Clinical Trial

Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis

Study acronym: Pso23
Recruiting
View on ClinicalTrials.gov →
Summary
This is a research study involving humans, of the interventional type with minimal risks and constraints (RIPH2). It is a monocentric, non randomized prospective study aiming to better understand the mechanisms of the response to anti-IL-23 biologics in psoriasis patients attending the dermatology department of hospital Cochin (APHP).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-10-27; most recent amendment 2025-05-13.
Status change: Not Yet Recruiting → Recruiting 2022-10-06
Trial Details
NCT Number NCT05111210
Lead Sponsor Institut Pasteur
Collaborators: Janssen Biotech, Inc.
Conditions Psoriasis
Enrollment 90 participants
Start Date 2021-12-14
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-14